profit from every $100 of sales.
$0$100
MBX Biosciences
$56.33+4.20% today
+134.0% in 1 year
1-year low $24.071-year high $70.70
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What MBX Biosciences sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $0 in 2025, with -$87.0 million of profit last year.
SalesProfit
MBX Biosciences vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| MBX Biosciences | No profit yet | ||
 Vertex Pharmaceuticals | 35.1× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 21.0× · Fair price | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads MBX Biosciences's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -25 | -35 | -68 | -98 | |
| -26 | -35 | -68 | -98 | |
| -26 | -33 | -62 | -87 | |
| -0.82 | -1.02 | -5.82 | -2.38 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 45 | 84 | 269 | 385 |
| Cash | 24 | 31 | 49 | 75 |
| Total debt | 0 | 0 | 0 | 1 |
| Total liabilities | 88 | 157 | 11 | 16 |
| -43 | -72 | 257 | 369 | |
| 32 | 32 | 11 | 37 | |
| – | – | -20.9% | -20.9% | |
| 61.3% | 44.9% | -24.1% | -23.6% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -23 | -32 | -55 | -80 | |
| 0 | 0 | 1 | 2 | |
| -24 | -32 | -56 | -82 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 0 | 2 | 5 | 9 |
Valuation
- –
- –
- –
- 3.4×
- –
- –
- –
- -3.0%
- -3.2%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -22.5%
- 14.9%
- -24.5%
- -19.1%
- -22.5%
- –
Growth
- –
- –
- −47.4%
- –
- +4.6%
Financial health
- 0.5×
- 0.00
- 0.1%
- –
- 30.79
- 30.79
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 20%of 952
Bottom 21%of 877
Bottom 25%of 988
What analysts expect
- Average price target
- $55.33
- Range
- $18.00 – $88.00
- 1 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 7, 2026 | -0.51 | -0.62 | +17.7% |
| Mar 12, 2026 | -0.49 | -0.64 | +23.4% |
| Nov 6, 2025 | -0.63 | -0.73 | +13.7% |
| Aug 7, 2025 | -0.58 | -0.77 | +24.7% |
| May 12, 2025 | -0.71 | -0.81 | +12.3% |
| Mar 17, 2025 | -0.47 | -0.59 | +20.3% |
| Nov 7, 2024 | -2.78 | -2.72 | −2.2% |
| Aug 23, 2024 | -11.47 | – | – |
News
Coherus BioSciences Q3 2026 Earnings PreviewSeeking Alpha · Nov 8, 2026Revelation Biosciences GAAP EPS of -$5.92Seeking Alpha · Nov 6, 2026Castle Biosciences signals $385M-$395M 2026 revenue outlook as TissueCypher targets 50%-52% volume growthSeeking Alpha · Nov 6, 2026Where Will Neurocrine Biosciences Be in 5 Years?Yahoo Finance · Oct 25, 2026Arcus Biosciences slides 20% on stock offering, kidney-cancer dataSeeking Alpha · Oct 21, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
27No pass
Benjamin Graham
40No pass
Philip Fisher
38No pass
Peter Lynch
60Pass
Joel Greenblatt
0No pass
Charlie Munger
36No pass
Terry Smith
33No pass
Questions about MBX Biosciences
Is MBX Biosciences a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the MBX Biosciences AI analysis
What does MBX Biosciences do?
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. It is in Biotechnology.
Does MBX Biosciences pay a dividend?
No. MBX Biosciences does not pay a dividend at the moment.
Is MBX Biosciences stock halal?
Yes. MBX Biosciences passes our halal screen: its business is permitted and its debt is under 0.1% of its market value, under the 30% limit. How we check
How has MBX Biosciences stock done over the past year?
Up 134.0% over the past twelve months, to $56.33. It traded between $24.07 and $70.70 and is 20.3% below its high.
Who are MBX Biosciences's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with MBX Biosciences's.
Prices: daily closes to Nov 10, 2026. Fundamentals: company reports via invest-like data.